2、百奥赛图(北京)医药科技股份有限公司于2025-12-10上市，公司主营业务为从事提供基因编辑服务、 临床前药理药效评估服务、模式动物销售、抗体开发及创新药开发。 3、百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司 通过五个分部开展业务。 来源：新浪证券-红岸工作室 2月26日，百奥赛图涨8.15%，成交额2.11亿元，换手率7.92%，总市值346.39亿元。 异动分析 AI智能体+科创次新股+CRO概念+人民币贬值受益+注册制次新股 1、2026年1月13日互动易：我们通过AI的本地化部署，正在建设抗体药物研发AI智能体。随着千鼠万 抗计划与AI系统深度整合的持续推进，我们将为全球药企提供更加高效的研发工具和更为丰富的抗体 分子库，帮助药企伙伴提高临床前PCC分子的研发效率，这也将推动抗体发现业务迈入全新发展阶段。 区间今日近3日近5日近10日近20日主力净流入218.42万-921.89万-975.39万2306.19万7132.04万 公司简介 4、根据2024年年报，公司海外营收占比为67.94%，受益于人民币贬值。 5、百奥赛图(北京)医药科技股份有限 ...

Core Viewpoint - Shandong Weigao Blood Purification Products Co., Ltd. is actively expanding its overseas business and is involved in a significant asset restructuring transaction to acquire 100% equity of Weigao Puri Pharmaceutical Packaging Co., Ltd. [3] Company Overview - Shandong Weigao Blood Purification Products Co., Ltd. specializes in the research, production, and sales of blood purification medical products, including blood dialysis devices, blood dialysis tubing, blood dialysis machines, and peritoneal dialysis solutions [2][3] - The company was established on December 27, 2004, and was listed on May 19, 2025 [3][7] - The revenue composition of the company includes consumables (77.55%), equipment (18.25%), and other categories (4.20%) [7] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 2.736 billion yuan, representing a year-on-year growth of 3.45% [7] - The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [7] - The company has distributed a total of 65.8213 million yuan in dividends since its A-share listing [8] Market Activity - On February 4, the stock price of Weigao Blood Purification increased by 0.17%, with a trading volume of 36.6268 million yuan and a turnover rate of 2.32%, resulting in a total market capitalization of 16.815 billion yuan [1] - The stock has seen a net outflow of 2.0387 million yuan from major investors today, with a continuous reduction in holdings over the past three days [4][5] Technical Analysis - The average trading cost of the stock is 41.25 yuan, with recent reductions in holdings slowing down [6] - The current stock price is fluctuating between a resistance level of 40.53 yuan and a support level of 39.80 yuan, indicating potential for range trading [6]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, production, and sales of medical imaging and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On January 15, 2025, the company's stock price fell by 3.56%, with a trading volume of 83.72 million yuan and a turnover rate of 5.99%, resulting in a total market capitalization of 10.207 billion yuan [1]. - The stock has seen a net outflow of 7.16 million yuan from major investors, indicating a reduction in holdings over the past two days [4][5]. Product and Industry Insights - The company showcased its innovative veterinary medical imaging products at the 97th WVC annual conference, engaging with industry experts and gaining valuable user insights [2]. - The industrial ultrasound products are primarily applied in non-destructive testing for water and electricity engineering, including pipelines and pressure vessels [2][3].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., has shown significant growth in its stock performance and is benefiting from various market trends, including the pet economy and medical device sector, as well as the depreciation of the RMB [1][2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on ultrasound technology [2][3]. - The company was established on November 15, 1982, and went public on January 22, 2025 [7]. - The main revenue sources for the company are medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [7][8]. - As of September 30, 2025, the company had a total market capitalization of 10.151 billion yuan [1]. Market Position and Trends - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. - The stock has experienced a recent increase of 5.15% in value, with a trading volume of 166 million yuan and a turnover rate of 12.02% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 23.90% to 17,000, while the average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which is a decrease of 388,200 shares compared to the previous period [9].

Core Viewpoint - The company, Zhejiang Zhongli Machinery Co., Ltd., focuses on the research, development, and sales of electric forklifts and intelligent industrial vehicles, with a strong emphasis on innovation and green technology [2][3]. Company Overview - Zhejiang Zhongli Machinery Co., Ltd. was established on September 20, 2007, and is located in Anji County, Huzhou City, Zhejiang Province. The company is set to be listed on December 24, 2024, with its main business involving the R&D, production, and sales of electric forklifts and other industrial vehicles [7]. - The company's revenue composition includes 98.85% from forklifts and related parts, and 1.15% from other sources [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 5.243 billion yuan, representing a year-on-year growth of 8.62%. The net profit attributable to shareholders was 685 million yuan, reflecting a growth of 5.46% [8]. - The company has distributed a total of 353 million yuan in dividends since its A-share listing [9]. Market Position and Trends - The company has a significant international presence, with overseas revenue accounting for 51.63%, benefiting from the depreciation of the RMB [3]. - The company aims to lead the industry transformation towards green, intelligent, and digital logistics, focusing on the transition from manual to electric handling and from diesel to lithium battery forklifts [3]. Stock Performance - As of December 19, the stock price of Zhongli shares increased by 0.55%, with a trading volume of 28.1361 million yuan and a turnover rate of 1.48%, resulting in a total market capitalization of 14.753 billion yuan [1]. - The average trading cost of the stock is 39.05 yuan, with the current price fluctuating between resistance at 37.73 yuan and support at 35.98 yuan [6].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on the pet economy and medical device sectors [2][3]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 254 million yuan, representing a year-on-year decrease of 2.90%. The net profit attributable to the parent company was approximately 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company had a total market capitalization of 9.338 billion yuan [1]. Market Position and Trends - The company benefits from a 55.26% share of overseas revenue, aided by the depreciation of the Chinese yuan [3]. - The stock has shown a recent increase of 1.07% with a trading volume of 23.52 million yuan and a turnover rate of 1.85% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders was approximately 17,000, a decrease of 23.90% from the previous period. The average number of circulating shares per person increased by 39.99% to 3,438 shares [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8][9]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On December 12, the company's stock price increased by 1.09%, with a trading volume of 22.8866 million yuan and a turnover rate of 1.76%, bringing the total market capitalization to 9.552 billion yuan [1]. - The stock has experienced a net outflow of 1.2743 million yuan from major investors today, indicating a lack of strong control by major shareholders, with a very dispersed distribution of shares [5][6]. Recent Developments - The company participated in the 97th WVC Annual Meeting from March 3 to 5, 2025, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2].

Core Viewpoint - The company, Zhejiang Zhongli Machinery Co., Ltd., focuses on the research, development, production, and sales of electric forklifts and other industrial vehicles, benefiting from the depreciation of the RMB and the growing demand for automation in logistics [2][3]. Company Overview - Zhejiang Zhongli Machinery Co., Ltd. was established on September 20, 2007, and is located in Xiaqian Village, Lingfeng Street, Anji County, Huzhou City, Zhejiang Province. The company specializes in electric forklifts and other industrial vehicles [7]. - The company went public on December 24, 2024, with its main business revenue composition being 98.85% from forklifts and related parts, and 1.15% from other sources [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 5.243 billion yuan, representing a year-on-year growth of 8.62%, and a net profit attributable to shareholders of 685 million yuan, up 5.46% year-on-year [8]. - The company has distributed a total of 353 million yuan in dividends since its A-share listing [9]. Market Position and Trends - The company operates in the machinery equipment sector, specifically in engineering machinery, and is part of several concept sectors including smart logistics, new industrialization, and new energy vehicles [8]. - As of September 30, 2025, the company had 18,200 shareholders, a decrease of 9.15% from the previous period, with an average of 2,834 circulating shares per person, an increase of 10.07% [8]. Product Development - The company has focused on technological research and product innovation in electric forklifts and other industrial vehicles, with a commitment to green, digital, and intelligent development [2]. - The company has developed several milestone products, including the "Little King Kong" electric forklift and the "搬马" (Moving Horse) robot series, which are designed to enhance automation and reduce manual handling [2].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant portion of its revenue coming from overseas due to the depreciation of the RMB [3][4]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business segments include medical ultrasound (71.16% of revenue), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and other supplementary products (1.26%) [7]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 254 million yuan, a year-on-year decrease of 2.90%, and a net profit attributable to shareholders of 88.94 million yuan, down 3.66% year-on-year [8]. - As of September 30, 2025, the company's overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [3]. Market Activity - On December 10, the company's stock price increased by 0.09%, with a trading volume of 17.43 million yuan and a turnover rate of 1.35%, resulting in a total market capitalization of 9.517 billion yuan [1]. - The stock has shown no significant trend in major capital inflows, with a net outflow of 1.4365 million yuan on the same day [4][5]. Shareholder Structure - As of September 30, 2025, the company had 17,000 shareholders, a decrease of 23.90% from the previous period, with an average of 3,438 shares held per shareholder, an increase of 39.99% [7]. - The largest shareholder is Huabao Zhongzheng Medical ETF, holding 1.5245 million shares, which decreased by 388,200 shares compared to the previous period [9].

Core Viewpoint - The company, Zhejiang Zhongli Machinery Co., Ltd., focuses on the research, development, production, and sales of electric forklifts and other industrial vehicles, benefiting from the depreciation of the RMB and the growing demand for automation in logistics [2][3]. Company Overview - Zhejiang Zhongli Machinery Co., Ltd. was established on September 20, 2007, and is located in Xiaqian Village, Lingfeng Street, Anji County, Huzhou City, Zhejiang Province. The company specializes in electric forklifts and other industrial vehicles [7]. - The company went public on December 24, 2024, with its main business revenue composition being 98.85% from forklifts and related parts, and 1.15% from other sources [7]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 5.243 billion yuan, representing a year-on-year growth of 8.62%. The net profit attributable to the parent company was 685 million yuan, with a year-on-year increase of 5.46% [8]. - As of September 30, 2025, the company had a total market capitalization of 15.11 billion yuan, with a trading volume of 63.34 million yuan on December 5, 2024 [1][8]. Market Position and Trends - The company is positioned within the machinery equipment sector, specifically in engineering machinery, and is part of several concept sectors including new industrialization, robotics, smart logistics, and new energy vehicles [8]. - The company has a significant overseas revenue share of 51.63%, benefiting from the depreciation of the RMB [3]. Product Development - The company has developed several milestone products, including the "Little King Kong" electric forklift, oil-to-electric forklifts, and the "搬马" (Moving Horse) robot series, which are designed to enhance automation and reduce inefficiencies in material handling [2].